# Article information:

Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer | ESMO
<https://www.esmo.org/guidelines/guidelines-by-topic/lung-and-chest-tumours/oncogene-addicted-metastatic-non-small-cell-lung-cancer>

# Article summary:

1. This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing oncogene-addicted mNSCLC.

2. The guideline covers diagnosis, staging, risk assessment, treatment and disease monitoring.

3. Recommendations are based on available scientific data and the authors’ collective expert opinion.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

The article is written by a group of experts in the field of oncology and is published by the European Society for Medical Oncology (ESMO). This indicates that the article is likely to be reliable and trustworthy as it has been written by experts in the field who have access to up-to-date research and evidence. The article also provides ESMO-MCBS scores to describe the levels of evidence for treatment choices, as well as ESCAT scores to describe the evidence level for genomic alterations as biomarkers for using targeted therapies.

However, there are some potential biases in the article that should be noted. For example, it does not present both sides equally; instead, it focuses solely on providing recommendations based on available scientific data and the authors’ collective expert opinion. Additionally, there may be missing points of consideration or unexplored counterarguments that could provide a more balanced view of the topic at hand. Furthermore, there may be promotional content or partiality in favour of certain treatments or therapies which could lead to an unbalanced view of the issue being discussed. Finally, possible risks associated with certain treatments or therapies may not be noted in sufficient detail which could lead to an incomplete understanding of potential risks associated with certain treatments or therapies.

# Topics for further research:

* Potential risks associated with targeted therapies
* Evidence-based treatment choices for oncology
* Biomarkers for using targeted therapies
* Unbalanced view of oncology treatments
* Promotional content in oncology articles
* Partiality in favour of certain treatments for oncology

# Report location:

<https://www.fullpicture.app/item/e9edfb52c4149cdd3d0438b130dc7ed8>